DEVELOPMENT OF THE “METRASTOMCHITHIAL” MOUTHWASH FORMULATION AS A MEANS OF POTENTIAL INFLUENCE ON THE MICROBIOME AND REGENERATION OF ORAL TISSUES IN POST-COVID-19 SYNDROME
DOI:
https://doi.org/10.11603/2311-9624.2025.1.15447Keywords:
post-acute sequelae COVID-19, post-Covid-syndrome, gingivitis, aphthous ulcers, regeneration, antimicrobial agent, elixir, hyaluronic acid, chitosan, chlorhexidine.Abstract
Long-term complications of COVID-19 are caused by the persistence of the oral pathogen SARS-CoV-2, which replicates and infects the epithelial cells of the oral mucosa, resulting in dysbiosis of the oral microbiome, inflammation, and inhibition of the immune resistance of the SARS. Reducing the oral bacterial and viral burden in the oral cavity can be achieved by using topical therapy, i.e., mouthwashes. The aim of the study is to develop a formulation and method for producing a mouthwash with potential pathogenic effects for patients with oral postacute complications of COVID-19. Materials and Methods. We used the methods of gravimetric analysis, potentiometry, capillary viscometry, and redeposition. Results and Discussion. The design of the mouthwash formulation developing was based on meeting the basic requirements for restoring the balance of the oral microbiome in the post-COVID-19 syndrome. We studied the potential mechanisms and hypotheses associated with SARSCoV- 2 infection and its long-term effects on oral health by using mouthwash in complex therapy as an adjunct in the treatment of oral manifestations of post- COVID-19. We have proposed the formulation of the “Metrastomhitgial” mouthwash, the components of which have a significant effect on potential pathogenic factors by reducing the oral viral burden, restoring the oral microbiome and accelerating the regeneration of damaged tissues. Conclusions. Considering the data on the potential impact of its components, in particular, a wide range of their antibacterial, antifungal effects, as well as their impact on viral pathogens in the context of the oral microbiome, it is likely that the complex composition of “Metrastomhitgial” mouthwash will contribute to the restoration of the oral microbiocenosis, reduce the burden of coronavirus in the oral cavity, reduce inflammation of the oral mucosa and regenerate damaged tissues in patients with post-COVID-19 syndrome.
References
La Rosa G. R. M., Libra M., De Pasquale R., Ferlito S., Pedullà E. Association of Viral Infections With Oral Cavity Lesions: Role of SARS-CoV-2 Infection. Front Med (Lausanne). 2021. No. 7. P. 571214. DOI: 10.3389/ fmed.2020.571214
Hao M., Wang D., Xia Q., Kan S., Chang L., Liu H., Yang Z., Liu W. Pathogenic Mechanism and Multiomics Analysis of Oral Manifestations in COVID-19. Front Immunol. 2022. No. 13. P. 879792. DOI: 10.3389/fimmu.2022.879792
Park J. Y. Post-acute infection syndrome after COVID-19: effects on the oral and maxillofacial region and the recent publication trends. J Korean Assoc Oral Maxillofac Surg. 2022. No. 48 (3). P. 131–132. DOI: 10.5125/ jkaoms.2022.48.3.131
Schwartz J., Capistrano K., Hussein H., Hafedi A., Shukla D. Naqvi A. Oral SARS-CoV-2 Infection and Risk for Long Covid. Rev Med Virol. 2025. No. 35 (2). Р. 70029. DOI: 10.1002/rmv.70029
Cegolon L., Mastrangelo G., Bellizzi S., Filon F. L., Salata C. Supporting the Aspecific Physiological Defenses of Upper Airways against Emerging SARS-CoV-2 Variants. Pathogens. 2023. No. 12 (2). Р. 211. DOI: 10.3390/ pathogens12020211
Fakhruddin K. S., Samaranayake L. P., Buranawat B., Ngo H. Orofacial mucocutaneous manifestations of Coronavirus Disease-2019 (COVID-19): A systematic review. PLoS One. 2022. No. 17 (6). Р. 0265531. DOI: 10.1371/journal.pone.0265531
Iqbal N. T., Khan H., Khalid A., Mahmood S. F., Nasir N., Khanum I., de Siqueira I., Van Voorhis W. Chronic inflammation in post-acute sequelae of COVID-19 modulates gut microbiome: a review of literature on COVID-19 sequelae and gut dysbiosis. Mol Med. 2025. No. 31 (1). Р. 22. DOI: 10.1186/s10020-024-00986-6
McGrat C., Clarkson J., Glenny A. M., Walsh L. J., Hua F. Effectiveness of Mouthwashes in Managing Oral Diseases and Conditions: Do They Have a Role? Int Dent J. 2023. No. 73 (Suppl 2). Р. 69–73. DOI: 10.1016/j.identj.2023.08.014
Гевкалюк Н. О., Пальчевський Т. В. Клініко-патогенетичні аспекти порушень стану органів порожнини рота в пацієнтів із постковідним синдромом. Клінічна стоматологія. 2024. № 3. С. 27–36. DOI: 10.11603/ 2311-9624.2024.3.14976
Гевкалюк Н., Пальчевський Т. Використання маркерів запалення для стратифікації захворювань слизової оболонки порожнини рота пацієнтів у постковідному періоді. Вісник стоматології. 2024. № 129 (4). С. 2–8. DOI: 10.35220/2078-8916-2024-54-4.1
Brookes Z. L. S., Belfield L. A., Ashworth A., Casas- Agustench P., Raja M., Pollard A. J., Bescos R. Effects of chlorhexidine mouthwash on the oral microbiome. J Dent. 2021. No. 113. Р. 103768. DOI: 10.1016/j.jdent.2021.103768
Yousefimanesh H., Amin M., Robati M., Goodarzi H., Otoufi M. Comparison of the Antibacterial Properties of Three Mouthwashes Containing Chlorhexidine Against Oral Microbial Plaques: An in vitro Study. Jundishapur J Microbiol. 2015. No. 8 (2). Р. 17341. DOI: 10.5812/jjm.17341
Brookes Z., Teoh L., Cieplik F., Kumar P. Mouthwash Effects on the Oral Microbiome: Are They Good, Bad, or Balanced? Int Dent J. 2023. No. 73 (Suppl 2). Р. 74–81. DOI: 10.1016/j.identj.2023.08.010
Aftab R., Dodhia V. H., Jeanes C., Wade R. G. Bacterial sensitivity to chlorhexidine and povidone-iodine antiseptics over time: a systematic review and metaanalysis of human-derived data. Sci Rep. 2023. No. 13 (1). Р. 347. DOI: 10.1038/s41598-022-26658-1
Casale M., Moffa A., Vella P., Rinaldi V, Lopez M. A., Grimaldi V., Salvinelli F. Systematic review: the efficacy of topical hyaluronic acid on oral ulcers. J Biol Regul Homeost Agents. 2017. No. 31 (4 Suppl 2). Р. 63–69. PMID: 29202564.
Rosa A., Pujia A. M., Arcuri C. Hyaluronic Acid Combined with Ozone in Dental Practice. Biomedicines. 2024. No. 12 (11). Р. 2522. DOI: 10.3390/biomedicines12112522
Casale M., Moffa A., Vella P., Sabatino L., Capuano F., Salvinelli B., Lopez M. A., Carinci F., Salvinelli F. Hyaluronic acid: Perspectives in dentistry. A systematic review. Int J Immunopathol Pharmacol. 2016. No. 29 (4). Р. 572–582. DOI: 10.1177/0394632016652906
Bhati A., Fageeh H,. Ibraheem W., Fageeh H., Chopra H., Panda S. Role of hyaluronic acid in periodontal therapy (Review). Biomed Rep. 2022. No. 17 (5). Р. 91. DOI: 10.3892/br.2022.1574
Milkova V., Vilhelmova-Ilieva N., Gyurova A., Kamburova K., Dimitrov I., Tsvetanova E., Georgieva A., Mileva M. Remdesivir-Loaded Nanoliposomes Stabilized by Chitosan / Hyaluronic Acid Film with a Potential Application in the Treatment of Coronavirus Infection. Neurol Int. 2023. No. 15 (4). Р. 1320–1338. DOI: 10.3390/neurolint15040083
Aghbashlo M., Amiri H., Moosavi Basri S. M., Rastegari H., Lam S. S., Pan J., Gupta V. K., Tabatabaei M. Tuning chitosan’s chemical structure for enhanced biological functions. Trends Biotechnol. 2023. No. 41 (6). Р. 785–797. DOI: 10.1016/j.tibtech.2022.11.009
Edo G. I., Yousif E., Al-Mashhadani M. H. Chitosan: An overview of biological activities, derivatives, properties, and current advancements in biomedical applications. Carbohydr Res. 2024. No. 542. Р. 109199. DOI: 10.1016/j.carres.2024.109199
Abourehab M. A. S., Pramanik S., Abdelgawad M. A., Abualsoud B. M., Kadi A., Ansari M. J., Deepak A. Recent Advances of Chitosan Formulations in Biomedical Applications. Int J Mol Sci. 2022. No. 23 (18). Р. 10975. DOI: 10.3390/ijms231810975
James P., Worthington H. V., Parnell C., Harding M., Lamont T., Cheung A., Whelton H., Riley P. Chlorhexidine mouthrinse as an adjunctive treatment for gingival health. Cochrane Database Syst Rev. 2017. No. 3 (3). CD008676. DOI: 10.1002/14651858.CD008676.pub2
Duane B., Yap T., Neelakantan P., Anthonappa R., Bescos R., McGrath C., McCullough M., Brookes Z. Mouthwashes: Alternatives and Future Directions. Int Dent J. 2023. No. 73 (Suppl 2). Р. 89–97. DOI: 10.1016/j.identj.2023.08.011
Zhang M., Meng N., Duo H., Yang Y., Dong Q., Gu J. Efficacy of mouthwash on reducing salivary SARS-CoV-2 viral load and clinical symptoms: a systematic review and meta-analysis. BMC Infect Dis. 2023. No. 23 (1). Р. 678. DOI: 10.1186/s12879-023-08669-z
Гевкалюк Н. О., Пальчевський Т. В. Оцінка інтенсивності запалення слизової оболонки порожнини рота за цитологічними ефектами оригінального препарату «Метрастомхітгіал» у пацієнтів із пост-Covid-19- синдромом [Наукова стаття]. 2024. Свідоцтво про авторське право на твір № 132025 від 11.12.2024.
Rautio J., Meanwell N. A., Di L., Hageman M. J. The expanding role of prodrugs in contemporary drug design and development. Nat Rev Drug Discov. 2018. No. 17 (8). Р. 559–587. DOI: 10.1038/nrd.2018.46
Jornada D. H., dos Santos Fernandes G. F., Chiba D. E., de Melo T. R., dos Santos J. L., Chung M. C. The Prodrug Approach: A Successful Tool for Improving Drug Solubility. Molecules. 2015. No. 21 (1). Р. 42. DOI: 10.3390/ molecules21010042
Sanches B. M. A., Ferreira E. I. Is prodrug design an approach to increase water solubility? Int J Pharm. 2019. No. 568. Р. 118498. DOI: 10.1016/j.ijpharm.2019.118498
Palchevskyі T. V., Gevkaliuk N. O. Candida albicans colonization of the mucous membrane in acute manifestations of COVID-associated oral candidasis. Regulatory Mechanisms in Biosystems. 2025. No. 16 (1). e25013. DOI: 10.15421/0225013
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 CLINICAL DENTISTRY
This work is licensed under a Creative Commons Attribution 4.0 International License.
